Full Breakdown
AI Chair at University of Alberta Targets Faster Drug Development and Smarter Cancer Imaging
6/8/2026, 10:58:51 AM
New Canada CIFAR AI Chair Aims to Transform Drug Development and Diagnostic Imaging
In January 2026 Dr. Amber Simpson was appointed a Canada CIFAR AI Chair and professor in the Department of Radiology and Diagnostic Imaging at the University of Alberta. Her mandate is to apply artificial-intelligence methods to design precision-targeted drugs and to create predictive algorithms for cancer imaging, shifting early-stage research from animal models to human-derived data.
Background & Context
Current drug pipelines rely heavily on animal testing, yet “seventy per cent of the drugs that have shown utility and are tested in animals have limited to no utility in humans.” Reducing animal use is a policy goal in many countries because it can lower costs, shorten timelines, and improve ethical standards. Parallel advances in AI and the availability of large, anonymized health-data repositories have opened a path to computational drug modelling that starts with human data.
Key Figures & Groups
- Dr. Amber Simpson – Canada CIFAR AI Chair, former Canada Research Chair in Biomedical Computing and Informatics (Queen’s University), affiliate of the Vector Institute.
- Canadian Institute for Advanced Research (CIFAR) – Provides a CAD $30 million investment through the Alberta Machine Intelligence Institute (Amii) to support the new AI chairs.
- Amii’s AI + Health Hub – Facilitates interdisciplinary collaboration across engineering, medicine, and data science.
- Dianne and Irving Kipnes Health Research Institute – Newly directed by Simpson, partially funded by the Dianne and Irving Kipnes Foundation.
Data & Statistics
- 70 % of animal-tested drug candidates fail to demonstrate efficacy in humans.
- Large human health data banks—including medical images, clinical notes, and genomic tests—are being mined to identify molecular targets and predict patient responses.
- International randomized trials have shown earlier detection of breast cancer when AI-powered screening tools are employed.
Why It Matters / Impact
By training models on high-dimensional human data, Simpson’s approach could:
- Reduce the number of animals required for pre-clinical testing, addressing both ethical concerns and cost.
- Accelerate the drug-development timeline, increasing the likelihood of clinical-trial success.
- Enhance diagnostic imaging by detecting subtle patterns invisible to the human eye, especially in regions with limited radiology expertise.
Regulatory bodies such as the U.S. FDA and Health Canada are already approving AI-driven tools, paving the way for clinical adoption.
Official Statements & Responses
CIFAR, via Amii, announced a CAD $30 million commitment to assemble leading AI researchers across disciplines, citing the need to “solve the hardest problems in artificial intelligence.” Simpson explained that her chair “allows a significant proportion of time to be dedicated to boundary-pushing research” and that the AI models “are getting approval from regulatory agencies such as the FDA and Health Canada, and are being adopted in clinical settings.” The university highlighted the AI + Health Hub as a catalyst for rapid translation of data-driven discoveries into patient care.
Verbatim Quotes
- “What can AI do that a human absolutely can’t do?” — Dr. Amber Simpson, Canada CIFAR AI Chair
- “Seventy per cent of the drugs that have shown utility and are tested in animals have limited to no utility in humans,” — Dr. Amber Simpson
- “Our hope is that it reduces the number of failures in clinical trials because you’ve started from actual human data,” — Dr. Amber Simpson
- “You can train a computer to look at all of them and to track these very minute changes, which then triggers the radiologist to go back and take another look at that one patient’s images.” — Dr. Amber Simpson
- “Simpson is convinced that patients will appreciate the relevance and value of AI in health care within the next decade.” — Dr. Amber Simpson
What’s Next
Simpson anticipates the first AI-derived drug breakthroughs in cardiovascular disease, a field with rapid progression and high prevalence. She is co-developing longitudinal models with Dr. Russ Greiner to integrate sequential imaging, blood tests, and treatment data for dynamic patient monitoring. The lab is actively recruiting master’s, PhD, and postdoctoral scholars from ethics, epidemiology, and biostatistics to expand the interdisciplinary team. Simpson also predicts that the University of Alberta could earn “another Nobel Prize for the U of A” in AI and health within the coming decade.
